STOCK TITAN

Anebulo Pharmaceuticals Inc - ANEB STOCK NEWS

Welcome to our dedicated news page for Anebulo Pharmaceuticals (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anebulo Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anebulo Pharmaceuticals's position in the market.

Rhea-AI Summary
Anebulo Pharmaceuticals, Inc. (ANEB) reported financial results for the second quarter of fiscal year 2024, including a decrease in operating expenses and net loss compared to the same period in fiscal 2023. The company announced key highlights such as the appointment of Richie Cunningham as CEO, adoption of selonabant as the generic name for ANEB-001, advancement of a selonabant IV formulation, and securing a credit facility of up to $10 million. Anebulo aims to develop treatments for acute cannabinoid intoxication and substance abuse, with a focus on Phase 3 studies for selonabant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
-
Rhea-AI Summary
Anebulo Pharmaceuticals, Inc. (ANEB) announces financial results for the three months ended September 30, 2023, and recent updates. The company highlighted the appointment of Richie Cunningham as CEO and Board Member, a positive Type B meeting with the FDA, presentation at major scientific meetings, securing a credit facility of up to $10 million, and strengthening its capital structure. Financial results for the quarter showed operating expenses of $2.5 million and a net loss of $2.5 million, with cash at $8.5 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Summary
Anebulo Pharmaceuticals appoints Bimal Shah to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Anebulo Pharmaceuticals appoints Richie Cunningham as CEO, replacing Simon Allen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Anebulo Pharmaceuticals announces financial results for Q4 FY2023 and recent updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Anebulo Pharmaceuticals to present at H.C. Wainwright conference and upcoming scientific conferences. Two oral presentations and one poster presentation scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
conferences
Rhea-AI Summary
FDA provides favorable input on studies to support ANEB-001 approval. Phase 2 trial completed exploring THC challenge dose of up to 60 mg. Positive feedback received from FDA for a new drug application. Focus on finalizing Phase 3 trial designs. Preliminary safety observations show well-tolerance of ANEB-001 with THC challenge doses of 40 mg and 60 mg. Full data expected in 4Q 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
none
Anebulo Pharmaceuticals Inc

Nasdaq:ANEB

ANEB Rankings

ANEB Stock Data

76.76M
3.90M
65.38%
28.1%
0.07%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Lakeway